Feature | May 06, 2014

Siemens Announces FDA Clearance of Artis one Angiography System

May 6, 2014 — Siemens Healthcare announced the U.S. Food and Drug Administration (FDA) has cleared the Artis one angiography system, optimized for broad clinical utilization. The Artis one is designed for routine interventions, including revascularizations of peripheral vessel occlusions, functional tests of dialysis shunts in patients with kidney failure, diagnostic or minimally invasive angiographic treatment of narrowed coronary arteries, and pacemaker implantations.


Flexible With Low Space Requirement

Despite being floor-mounted, the Artis one features a positioning flexibility similar to ceiling-mounted systems and occupies just 269 square feet, compared to the standard 484 square feet required by ceiling-mounted systems. The system features several axes that can move independently of each other, enabling physicians and hospital staff to easily position the system where needed, regardless of where they stand. It accommodates full head-to-toe coverage of patients up to 6 feet, 10 inches without the need for patient repositioning. The system also allows free access to the patient's head, enabling optimal care during the procedure.

Tactile buttons on the Artis one’s tableside console can be manipulated easily even under the sterile covering. The on-screen, menu-guided user interface allows the physician to navigate directly using the heads-up display. All information regarding the procedure remains directly in front of the operator. And the 30-inch display size delivers images up to 90 percent larger than conventional 19-inch monitors.


Premium Cardio Applications, Powerful X-ray Tube

Artis one’s Clearstent Live application for interventional cardiology procedures — previously available only with Artis Q and Artis Q.zen — freezes motion in the region of the stent, allowing the physician to mask out movement of the beating heart and place the stent in precisely the correct position. The Artis one also offers new tools for cardiac imaging, including HeartSweep, which uses dual-axis rotational angiography to image the entire heart in a single, smooth C-arm movement instead of multiple acquisitions from different projections. This single-sweep movement has the potential to speed up procedures and save contrast agents. By utilizing 20 percent less energy than the Artis zee floor system, the Artis one also helps reduce operational costs.

The Artis one angiography system is available in multiple configurations.

For more information: www.usa.siemens.com/healthcare

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init